Why the study?
Does low-dose spironolactone reduce blood pressure and urinary albumin excretion in obese patients with essential hypertension and target organ damage on chronic ACE inhibitor therapy?
Population
21 obese subjects with essential hypertension and preexistent target organ damage, mean age 57.3 +/- 7.1…
Comparison
Spironolactone 12.5 mg/d added to chronic ACE… vs Pre-treatment baseline (pre-post study design).
Design
Cohort
Follow-up
4 weeks
Key result
Low-dose spironolactone (12.5 mg/d) added to chronic ACE inhibitor therapy significantly reduced mean office blood pressure (110.6 to 105.0 mmHg, P=0.004) and urinary albumin excretion.
Authors
Loading...
Supports adjunctive low-dose spironolactone in obese ACEI-treated hypertensives with target organ damage; leaves open RCT confirmation of outcomes.
Does low-dose spironolactone reduce blood pressure and urinary albumin excretion in obese patients with essential hypertension and target organ damage on chronic ACE inhibitor therapy?
The addition of low-dose spironolactone to chronic ACE inhibitor therapy significantly reduces blood pressure and albuminuria in obese hypertensive patients with target organ damage, without significantly increasing serum potassium.
Absolute Event Rate: 105% vs 110.6%
p-value: p=0.004
Bomback et al. (2009) studied obese subjects with essential hypertension and preexistent target organ damage (n=21). Spironolactone vs. Baseline (pre-treatment) was evaluated on mean office blood pressure (mmHg) (p=0.004). Low-dose spironolactone (12.5 mg/d) added to chronic ACE inhibitor therapy significantly reduced mean office blood pressure (110.6 to 105.0 mmHg, P=0.004) and urinary albumin excretion.